Background
Anemia, which is common in the critically ill, is often treated with red-cell transfusions which are associated with poor clinical outcomes. We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions.
Methods
Objective: Evaluate the effi cacy of epoetin alfa in reducing the packed red blood cell transfusion requirement in critically ill patients. Design: Prospective, randomized, double blind, placebo controlled, multi-center trial Setting: 115 medical centers throughout the United States. Subjects: 1460 patients that had been admitted to medical, surgical, or trauma intensive care units. Inclusion criteria included age 18 years or greater, patients remained in the ICU for two days, and hemoglobin level less than 12 gm/dl. Statistical analysis was performed for the entire group, as well as subgroup analysis according to the type of ICU to which the patient was admitted (the subgroup analysis was included in the initial study design). Intervention: After enrollment, patients randomized to the study group received epoetin alfa 40,000 units SQ on study day 1, 8, and 15. Th e drug was withheld if the hemoglobin level was greater than 12 gm/dl at the time of scheduled administration. Patients randomized to the placebo group received a placebo injection according to the same schedule. All patients enrolled received supplemental iron. Patients were given packed red blood cell transfusions at the discretion of the treating physician. Th e investigators recommended goal hemo globin concentration of 7 to 9 gm/dl, and not to transfuse for a hemoglobin concentration of greater than 9 gm/dl unless a specifi c indication was present. Outcomes: Th e primary endpoint was percentage of patients requiring blood transfusion. Secondary endpoints included number of units transfused, mortality, and the change in hemoglobin concentration from baseline.
Results
As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% confi dence interval [CI], 0.85 to 1.06) or the mean (±SD) number of red-cell units transfused (4.5±4.6 units in the epoetin alfa group and 4.3±4.8 units in the placebo group, P = 0.42). However, the hemoglobin concentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6±2.0 g per deciliter vs. 1.2±1.8 g per deciliter, P<0.001). Mortality tended to be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56 to 1.10); this eff ect was also seen in pre-specifi ed analyses in those with a diagnosis of trauma (adjusted hazard ratio, 0.37; 95% CI, 0.19 to 0.72). A similar pattern was seen at day 140 (adjusted hazard ratio, 0.86; 95% CI, 0.65 to 1.13), particularly in those with trauma (adjusted hazard ratio, 0.40; 95% CI, 0.23 to 0.69). As compared with placebo, epoetin alfa was associated with a signifi cant increase in the incidence of thrombotic events (hazard ratio, 1.41; 95% CI, 1.06 to 1.86).
Conclusions
Th e use of epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events. (ClinicalTrials.gov number, NCT00091910.)
Commentary
Anemia is a common problem in critically ill patients, frequently requiring packed red blood cell transfusion. Transfusions are associated with potential complications (hemolytic transfusion reactions, non-hemolytic transfusion reactions, infectious disease transmissions). Previous studies investigated the administration of human recombinant erythropoietin to critically ill patients to reduce transfusion requirements. Th e fi rst of these studies demonstrated fewer transfusions with the administration of erythropoietin, though there was no diff erence in mortality.
1 A similar, larger study was performed by many of the same researchers fi nding a similar decrease in transfusion requirements in the treatment group and no overall mortality diff erence. 2 Additionally, in a post hoc subgroup analysis, they identifi ed a mortality benefi t in trauma patients.
Th e current article was performed in order to investigate additional outcomes, primarily the safety of epoetin alfa for this indication. Th e study design was virtually the same as the 2002 study, although the current study evaluates mortality benefi t at 140 days (an extended time period from conventional 28-day mortality), and predetermined subgroup analysis of medical, surgical, and trauma ICU patients. It is interesting that the fi ndings of this study do not refl ect the transfusion benefi t previously demonstrated.
Th e current trial shows no diff erence in the PRBC transfusion requirements, no clinically signifi cant diff erence in hemoglobin concentration (though there is a statistical diff erence), and no mortality benefi t. So, what is the signifi cance of this study? Th e importance of this study lies within the predetermined subgroup analysis. In these analyses, mortality benefi t was observed in the trauma patients, both at 29 days (hazard ratio [HR]=0.37, CI:0.19 -0.72) and at 140 days (HR=0.40, CI: 0.23 -0.69). Th e mortality benefi t found in this data is not new. Similar fi ndings were shown in the previous trial, where a post hoc subgroup analysis was performed in trauma patients and mortality benefi t was observed at 29 days (HR=0.43, CI: 0.23 -0.81). Th us, two large studies have now shown a mortality benefi t. However, the causal mechanisms are unclear. Th e benefi t does not correspond to improvement in hemoglobin concentration or reduction in transfusion requirement. Th e authors speculate that it may be related to non-erythrogenic properties of epoetin alfa, such as anti-apoptotic characteristics or protection against hypoxemia.
Th e safety evaluation in this trial showed that epoetin alfa increases the incidence of clinically relevant thrombotic events (16.5 vs. 11.5, p = 0.008). Th ese fi ndings, however, are not entirely conclusive. With further analysis, the authors showed that the increase in throm botic events only aff ected patients not receiving heparin prophylaxis. Th e incidence of thrombotic events was 20.3 vs. 12.8 (p=0.008) in patients not receiving prophylaxis, and 12.3 vs. 10.2 (p=0.41) in patients receiving prophylaxis.
As with previous trials, this is a large, multi-center, prospective, blinded, placebo-controlled trial. Why then is the transfusion requirement benefi t not reproduced in this study? Th is diff erence is likely related to a change in transfusion culture. In 1999, the TRICC trial was published, and this study showed that a restrictive transfusion approach had similar outcomes compared to liberal transfusion strategy. 3 Previous trials recruited patients prior to these fi ndings, whereas the current study recruited patients after dissemination of fi ndings of the TRICC study. Th e lack of diff erences in transfusion requirement in this study may have occurred due to less aggressive transfusion practices.
With the current fi ndings, it is evident that epoetin alfa administered to critically ill patients does not improve transfusion requirements as previously demonstrated. Th e mortality benefi t shown in trauma patients should be considered, as this benefi t has been found independent of transfusion requirement and hemoglobin concentrations in two well designed trials. Mechanisms underlying this benefi cial eff ect should be examined in future studies. It is likely that epoetin alfa can be administered safely to critically ill patients that are also receiving heparin in prophylactic doses.
Recommendations
Epoetin alfa should not be used in critically ill patients to decrease PRBC requirements. Epoetin alfa can be considered in critically ill trauma patients as there is a demonstrated mortality benefi t, but these patients should be able to safely receive prophylactic heparin.
